Claybrook Capital’s Amgen AMGN Stock Holding History

Claybrook Capital’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-17,425	Closed	-$4.25M	–	134
2021 Q2	$4.25M	Buy	+17,425	New	+$4.29M	1.38%	16
2019 Q1	–	Sell	-273	Closed	-$53K	–	120
2018 Q4	$53K	Buy	+273	New	+$53.3K	0.01%	257

Other funds holding AMGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Claybrook Capital's AMGN Position: Q3 2021 in Review

Claybrook Capital sold out of Amgen (AMGN) in Q3 2021, closing a stake of 17,425 shares — an estimated $4.25M sold.

Claybrook Capital first reported a position in AMGN in Q4 2018 and held it in 2 quarters. The position peaked at $4.25M in Q2 2021. 2,132 funds tracked by Wall St. Rank hold AMGN as of Q3 2021.

Claybrook Capital reported no remaining Amgen position as of Q3 2021 after selling out during the quarter.
Claybrook Capital sold 17,425 Amgen shares in Q3 2021, an estimated $4.25M.
Claybrook Capital first reported a position in Amgen in Q4 2018 and held it in 2 quarters.
Claybrook Capital's Amgen position peaked at $4.25M in Q2 2021.
2,132 funds tracked by Wall St. Rank held Amgen as of Q3 2021.

Based on Claybrook Capital's 13F filing for Q3 2021, filed 15 Nov 2021.